Tania Dempsey, MD, discusses mast cell activation syndrome., which may be a consideration if a patient has not responded to anything else. Simple methods for treating and assessing patients are discussed.
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
In this detailed webinar on systemic mastocytosis, Dr. Miti introduces Professor Prithviraj Bose, an expert in the field, who discusses the complexities of diagnosing and managing systemic mastocytosis…
Presented by the Florida Society of Clinical Oncology, this program provides opportunities for patients and caregivers to learn and share information regarding a diagnosis of systemic mastocytosis. Pankit…
Surgeon Commander VA Arun, INHS Asvini, Colaba, Mumbai, and Anil Handoo, MD, BLK-Max Superspeciality Hospital, Delhi, discuss systemic mastocytosis. They review classification and diagnostic criteria and the clinical…
